Bank of Montreal Can Buys 222,167 Shares of Hologic, Inc. (NASDAQ:HOLX)

Bank of Montreal Can increased its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 45.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 714,377 shares of the medical equipment provider's stock after purchasing an additional 222,167 shares during the period. Bank of Montreal Can owned about 0.32% of Hologic worth $51,499,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Norges Bank acquired a new position in shares of Hologic in the 4th quarter worth approximately $133,414,000. Boston Partners grew its holdings in shares of Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after purchasing an additional 1,602,463 shares during the last quarter. Nordea Investment Management AB increased its stake in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock valued at $159,911,000 after buying an additional 544,889 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Hologic in the fourth quarter valued at about $27,007,000. Finally, Arrowstreet Capital Limited Partnership lifted its position in Hologic by 27.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,687,347 shares of the medical equipment provider's stock worth $121,641,000 after buying an additional 361,539 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HOLX. Citigroup dropped their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Evercore ISI lowered their target price on Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. Raymond James reaffirmed an "outperform" rating and set a $90.00 price target (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. William Blair reiterated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Finally, Stephens restated an "overweight" rating and set a $84.00 target price on shares of Hologic in a research report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $84.62.

Hologic Stock Down 1.3 %

HOLX stock traded down $0.75 during mid-day trading on Tuesday, hitting $58.09. 588,642 shares of the company were exchanged, compared to its average volume of 2,694,065. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 1-year low of $56.27 and a 1-year high of $84.67. The firm's 50 day simple moving average is $62.19 and its 200 day simple moving average is $71.34. The firm has a market cap of $13.03 billion, a P/E ratio of 18.32, a P/E/G ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.